Announcement on the Receipt of Clinical Trial Notification for KC1036 Combined with PD-1/PD-L1 Antibody in the Treatment of Advanced Solid Tumors

About this update from Beijing Konruns Pharmaceutical Co., Ltd. Class A

Announcement on the Receipt of Clinical Trial Notification for KC1036 Combined with PD-1/PD-L1 Antibody in the Treatment of Advanced Solid Tumors The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Beijing Konruns Pharmaceutical Co., Ltd. Class A